Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep 2022.
Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
You may not be if
Incomplete medical history
Clareo Health | Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
